DK3328864T3 - Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser - Google Patents
Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser Download PDFInfo
- Publication number
- DK3328864T3 DK3328864T3 DK16820570.6T DK16820570T DK3328864T3 DK 3328864 T3 DK3328864 T3 DK 3328864T3 DK 16820570 T DK16820570 T DK 16820570T DK 3328864 T3 DK3328864 T3 DK 3328864T3
- Authority
- DK
- Denmark
- Prior art keywords
- disorders
- compositions
- treatment
- therapeutic compounds
- substance abuse
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015902659A AU2015902659A0 (en) | 2015-07-06 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | |
| PCT/AU2016/050588 WO2017004674A1 (en) | 2015-07-06 | 2016-07-06 | Therapeutic compounds and compositions for treating social disorders and substance use disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3328864T3 true DK3328864T3 (da) | 2022-12-05 |
Family
ID=57684596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16820570.6T DK3328864T3 (da) | 2015-07-06 | 2016-07-06 | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11033555B2 (da) |
| EP (1) | EP3328864B1 (da) |
| JP (2) | JP7089825B2 (da) |
| KR (1) | KR20180023992A (da) |
| CN (1) | CN107922420B (da) |
| AU (1) | AU2016289271B2 (da) |
| CA (1) | CA2991236A1 (da) |
| DK (1) | DK3328864T3 (da) |
| ES (1) | ES2932194T3 (da) |
| HK (1) | HK1252813A1 (da) |
| HU (1) | HUE060496T2 (da) |
| IL (1) | IL256684B (da) |
| MX (1) | MX2017017171A (da) |
| NZ (1) | NZ738672A (da) |
| PL (1) | PL3328864T3 (da) |
| PT (1) | PT3328864T (da) |
| RU (1) | RU2715384C2 (da) |
| SI (1) | SI3328864T1 (da) |
| WO (1) | WO2017004674A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2932194T3 (es) | 2015-07-06 | 2023-01-16 | Kinoxis Therapeutics Pty Ltd | Compuestos terapéuticos y composiciones para el tratamiento de trastornos sociales y trastornos por uso de sustancias |
| MX2019006942A (es) * | 2016-12-12 | 2019-10-21 | Univ Sydney | Agonistas de receptores de oxitocina no peptidicos. |
| US20220079953A1 (en) * | 2018-11-23 | 2022-03-17 | The University Of Sydney | Methods for management of weight |
| KR20220063198A (ko) * | 2019-09-06 | 2022-05-17 | 키녹시스 테라퓨틱스 피티와이 리미티드 | 아편유사제 금단의 치료 |
| CA3191811A1 (en) * | 2020-09-07 | 2022-03-10 | Hugh ALSOP | Salts and crystals |
| AU2021401996A1 (en) * | 2020-12-14 | 2023-07-13 | Kinoxis Therapeutics Pty Ltd | Oxytocin receptor modulators |
| CN117279647A (zh) * | 2021-03-18 | 2023-12-22 | 金奥克斯治疗有限公司 | 治疗方法 |
| CN115677585B (zh) * | 2022-10-31 | 2024-03-19 | 上海群力化工有限公司 | 一种甲醛吡唑衍生物的合成工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115515D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Oxytocin agonisys |
| EP1512687A1 (en) | 2003-09-05 | 2005-03-09 | Ferring B.V. | Piperazines as oxytocin agonists |
| EP1632494A1 (en) * | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| RU2008114374A (ru) | 2005-10-24 | 2009-12-10 | Вайет (Us) | Трициклические соединения, применяемые в качестве агонистов рецептора окситоцина |
| GB0903493D0 (en) * | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
| ES2932194T3 (es) | 2015-07-06 | 2023-01-16 | Kinoxis Therapeutics Pty Ltd | Compuestos terapéuticos y composiciones para el tratamiento de trastornos sociales y trastornos por uso de sustancias |
| KR20220063198A (ko) | 2019-09-06 | 2022-05-17 | 키녹시스 테라퓨틱스 피티와이 리미티드 | 아편유사제 금단의 치료 |
-
2016
- 2016-07-06 ES ES16820570T patent/ES2932194T3/es active Active
- 2016-07-06 MX MX2017017171A patent/MX2017017171A/es unknown
- 2016-07-06 PL PL16820570.6T patent/PL3328864T3/pl unknown
- 2016-07-06 US US15/738,532 patent/US11033555B2/en active Active
- 2016-07-06 KR KR1020187003161A patent/KR20180023992A/ko not_active Application Discontinuation
- 2016-07-06 EP EP16820570.6A patent/EP3328864B1/en active Active
- 2016-07-06 SI SI201631630T patent/SI3328864T1/sl unknown
- 2016-07-06 NZ NZ738672A patent/NZ738672A/en unknown
- 2016-07-06 PT PT168205706T patent/PT3328864T/pt unknown
- 2016-07-06 JP JP2018500416A patent/JP7089825B2/ja active Active
- 2016-07-06 DK DK16820570.6T patent/DK3328864T3/da active
- 2016-07-06 CN CN201680040337.2A patent/CN107922420B/zh active Active
- 2016-07-06 CA CA2991236A patent/CA2991236A1/en active Pending
- 2016-07-06 RU RU2018103873A patent/RU2715384C2/ru active
- 2016-07-06 AU AU2016289271A patent/AU2016289271B2/en active Active
- 2016-07-06 HU HUE16820570A patent/HUE060496T2/hu unknown
- 2016-07-06 WO PCT/AU2016/050588 patent/WO2017004674A1/en active Application Filing
-
2018
- 2018-01-01 IL IL256684A patent/IL256684B/en unknown
- 2018-09-20 HK HK18112118.2A patent/HK1252813A1/zh unknown
-
2021
- 2021-05-07 US US17/314,664 patent/US11890287B2/en active Active
-
2022
- 2022-06-07 JP JP2022092261A patent/JP2022130418A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11033555B2 (en) | 2021-06-15 |
| US20220362261A1 (en) | 2022-11-17 |
| ES2932194T3 (es) | 2023-01-16 |
| EP3328864B1 (en) | 2022-09-07 |
| SI3328864T1 (sl) | 2023-02-28 |
| RU2018103873A3 (da) | 2019-09-04 |
| AU2016289271A1 (en) | 2018-01-25 |
| JP7089825B2 (ja) | 2022-06-23 |
| IL256684A (en) | 2018-03-29 |
| CN107922420B (zh) | 2021-12-31 |
| US20190290658A1 (en) | 2019-09-26 |
| RU2018103873A (ru) | 2019-08-06 |
| IL256684B (en) | 2022-06-01 |
| PT3328864T (pt) | 2022-12-07 |
| CA2991236A1 (en) | 2017-01-12 |
| CN107922420A (zh) | 2018-04-17 |
| HK1252813A1 (zh) | 2019-06-06 |
| RU2715384C2 (ru) | 2020-02-27 |
| HUE060496T2 (hu) | 2023-03-28 |
| EP3328864A1 (en) | 2018-06-06 |
| AU2016289271B2 (en) | 2020-12-03 |
| EP3328864A4 (en) | 2019-01-09 |
| JP2018525351A (ja) | 2018-09-06 |
| US11890287B2 (en) | 2024-02-06 |
| MX2017017171A (es) | 2018-04-30 |
| BR112018000059A2 (pt) | 2018-09-04 |
| JP2022130418A (ja) | 2022-09-06 |
| WO2017004674A1 (en) | 2017-01-12 |
| KR20180023992A (ko) | 2018-03-07 |
| NZ738672A (en) | 2022-11-25 |
| PL3328864T3 (pl) | 2023-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3326641T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
| DK3350157T3 (da) | Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3889145T3 (da) | 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme | |
| DK3402499T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3600270T3 (da) | Forbindelser og sammensætninger til behandling af hæmatologiske lidelser | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3153169T3 (da) | Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt | |
| DK3277270T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3157522T3 (da) | Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste | |
| DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted |